Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year. However, anticoagulation can increase the risk of bleeding, the study evaluating the role of oral anticoagulation is needed in this patients. This study …

  • 0 views
  • 24 Jan, 2021
API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous

  • 8 views
  • 05 Mar, 2021
  • 120 locations
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.

Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation. In these patients, international guidelines recommend indefinite anticoagulation. However, prolonged use of warfarin or DOAC at therapeutic dose is associated with a significant risk of bleeding. Consequently, it …

rivaroxaban
apixaban
anticoagulation therapy
aspirin
anticoagulants
  • 7 views
  • 27 Jan, 2021
  • 59 locations
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

The study aims to describe the biochemical coagulation profile and investigate the effect of Low molecular weight heparin and Apixaban on this profile in patients with nephrotic syndrome.

  • 0 views
  • 30 Apr, 2021
  • 1 location
TXA and Corona Virus 2019 (COVID19) in Outpatients

A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

covid-19
  • 62 views
  • 24 Feb, 2021
  • 1 location
A Multi-center Study of Apixaban(APPROACH)

The aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban (5 mg bid

  • 0 views
  • 25 Jan, 2021
  • 1 location
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients

Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.

  • 39 views
  • 22 Feb, 2021
  • 2 locations